Besides having a pivotal role for the success of an experimental therapeutic application of TRAIL or DR5 agonists, inhibition of Notch1 signaling might also be interesting with regard to an efficient TRAIL-mediated immunologic tumor defense. This evidence concerns the gene TNFSF10 and neoplasm.